Benjamin Wind, DO
Pulmonary Disease · Philadelphia, PANPI 1831279488
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $130,320 of the $167,947 with a category attached, or 77.6%. 31 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 45.8% of the total. Among pulmonary disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 393 payments — averaging $427.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$77K
- United Therapeutics Corporation$73K
- Bayer$15K
- GSK$466
- AstraZeneca$333
- Merck$259
- plus $2K from 25 others
What the payments were for
- Consulting fees$15,9509%
- Speaking & faculty fees$130,32078%
- Travel & lodging$10,3386%
- Food & beverage$11,1087%
- Education$2310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 129 | $76,921 |
| United Therapeutics Corporation | 121 | $73,243 |
| Bayer | 14 | $14,994 |
| GSK | 29 | $466 |
| AstraZeneca | 16 | $333 |
| Merck | 8 | $259 |
| Insmed, Inc. | 6 | $226 |
| Boehringer Ingelheim | 12 | $222 |
| Mylan Specialty L.p. | 8 | $148 |
| Pulmonx Corporation | 1 | $143 |
| Alnylam Pharmaceuticals Inc. | 1 | $123 |
| Philips North America LLC | 8 | $121 |
| Grifols USA, LLC | 3 | $89 |
| Genentech USA, Inc. | 6 | $87 |
| Amgen | 2 | $71 |
| Novartis | 4 | $70 |
| Electromed, Inc. | 5 | $59 |
| Verona Pharma, Inc. | 2 | $52 |
| Baxter Healthcare | 1 | $43 |
| Sandoz | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 3 | $35 |
| Sanofi | 2 | $34 |
| Harmony Biosciences LLC | 1 | $29 |
| Pfizer | 2 | $27 |
| Lilly USA, LLC | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Bridgebio Pharma, Inc. | 1 | $14 |
| Novo Nordisk | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$74,227
- OPSUMIT$74,148
- TYVASO$23,453
- Adempas$14,791
- ORENITRAM$253
- CHARTIS CATHETER$143
- ZEPHYR DELIVERY CATHETER$143
- ZEPHYR ENDOBRONCHIAL VALVE$143
- PULMONX CHARTIS TABLET CONSOLE$143
- AMVUTTRA$123
- WINREVAIR$123
- Arikayce$108
- REMODULIN$108
How this compares
$167,947 in reported general payments places this provider in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 149 | $3,608,105 |
| OpsumitMacitentan | 125 | $1,538,616 |
| OfevNintedanib Esylate | 45 | $660,148 |
| UptraviSelexipag | 23 | $584,301 |
| AdempasRiociguat | 43 | $575,874 |
| Orenitram ErTreprostinil Diolamine | 35 | $500,126 |
| WinrevairSotatercept-Csrk | 24 | $374,598 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 276 | $286,009 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 310 | $275,514 |
| Tadalafil | 161 | $175,465 |
| Pirfenidone | 37 | $153,006 |
| TezspireTezepelumab-Ekko | 29 | $126,313 |
| Ambrisentan | 26 | $66,602 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 84 | $58,414 |
| Sildenafil Citrate | 119 | $52,269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $76,921 | $2,122,917148 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $222 | $703,32897 claims |
| BayerAdempas | $14,994 | $575,87443 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Bevespi Aerosphere, Airsupra | $333 | $451,077419 claims |
| MerckWinrevair | $259 | $374,59824 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $466 | $351,003373 claims |
| PfizerEliquis | $27 | $10,48918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Philadelphia
- Gerard CrinerPhiladelphia$657K
- Parth RaliPhiladelphia$314K
- Steven GellerPhiladelphia$274K
- Christopher ManleyPhiladelphia$262K
- Jeffrey EdelsonPhiladelphia$233K
- Boyd HehnPhiladelphia$157K
- Gary AaronsonPhiladelphia$122K
- Friedrich KueppersPhiladelphia$100K
- Philip SilkoffPhiladelphia$88K
- Jeffrey ThompsonPhiladelphia$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.